LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study.Chin Med J (Engl)已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other。 | PMID 39965795PMC12634238 | 2025-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.J Clin Oncol | PMID 41082707PMC12622289 | 2025-Nov-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41101087无 PMCID | 2025-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41259756无 PMCID | 2025-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Psychometric evaluation of a pediatric functional constipation symptom diary using randomized phase 3 clinical trial data.J Patient Rep Outcomes已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。 | PMID 41264134PMC12635004 | 2025-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Agreement between face-to-face and photograph and video assessments in children with Bell's palsy: secondary analysis of a randomised controlled trial.Arch Dis ChildPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40634111无 PMCID | 2025-Nov-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up).Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40581082无 PMCID | 2025-Nov-18 | 0.95 | Study is not oncology-related; the primary efficacy endpoint is the proportion achieving EASI 90 at week 24, a binary categorical endpoint, not a time-to-event outcome. | 无 KM 图 |
| Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40737559无 PMCID | 2025-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa.Br J Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40794600无 PMCID | 2025-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40892617无 PMCID | 2025-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.J Am Heart AssocPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41195787PMC12887200 | 2025-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients.Am J Hypertens已检查 5 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 forest plot;Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图。 | PMID 40397037PMC12620020 | 2025-Nov-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.J Clin Invest已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图;Figure 3:ROC 图;Figure 4:AI 判定为 other。 | PMID 40924496PMC12618077 | 2025-Nov-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41045691无 PMCID | 2025-Nov-17 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41130252无 PMCID | 2025-Nov-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A qualitative study of Emotion and Symptom-focused Engagement (EASE): An integrated psychotherapeutic and early palliative care intervention for patients with acute leukemia.Support Care Cancer入排复审未纳入:The record describes a qualitative sub-study embedded within a larger Phase III RCT. While the parent trial is definitive and oncology-focused, this specific report does not report the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. It is a qualitative process report, not an efficacy or outcomes report. | PMID 41240159无 PMCID | 2025-Nov-15 | 0.85 | The record describes a qualitative sub-study embedded within a larger Phase III RCT. While the parent trial is definitive and oncology-focused, this specific report does not report the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. It is a qualitative process report, not an efficacy or outcomes report. | 无 KM 图 |
| Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II).MedAI 判定该论文不进入自动 KM 提取:This record explicitly reports results from Phase 2 of a seamless Phase 2/3 trial. The primary endpoint presented is the Phase 2 complete response rate, not the Phase 3 disease-free survival rate. Therefore, it is not a Phase III report. | PMID 40845854无 PMCID | 2025-Nov-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41072276无 PMCID | 2025-Nov-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41092804无 PMCID | 2025-Nov-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.Arthritis Res Ther已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 forest plot;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 41239458PMC12619491 | 2025-Nov-14 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41124233无 PMCID | 2025-Nov-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.NeurologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41071964无 PMCID | 2025-Nov-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:森林图/亚组分析图;Figure 3.:森林图/亚组分析图。 | PMID 40239134PMC12228211 | 2025-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40632972无 PMCID | 2025-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.J Clin OncolAI 判定该论文不进入自动 KM 提取:The record is a combined phase II/III trial, not solely a phase III trial. The primary endpoint for the phase III component (6-month HVLT-R DR failure) did not meet statistical significance, and the trial is not exclusively phase III. | PMID 40789106PMC12342643 | 2025-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41115436无 PMCID | 2025-Nov-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41125110无 PMCID | 2025-Nov-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.J Neurol已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。 | PMID 41205003PMC12596324 | 2025-Nov-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40960239无 PMCID | 2025-Nov-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.N Engl J Med | PMID 41191939PMC7618363 | 2025-Nov-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41191940无 PMCID | 2025-Nov-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Anxiety, repetitive and restricted behaviors and interests, and social communication in autistic adults: an exploratory analysis of a phase 3, randomized clinical trial.Sci Rep入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41198718PMC12592728 | 2025-Nov-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir.Antimicrob Agents Chemother已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 other;Fig 2:AI 判定为 other;Fig 3:AI 判定为 other;Fig 4:AI 判定为 other。 | PMID 40965470PMC12587539 | 2025-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Metronidazole exposure-response and safety in infants.Antimicrob Agents ChemotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40970766PMC12587542 | 2025-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.Eur Heart J Cardiovasc Pharmacother | PMID 40839760PMC12582660 | 2025-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 40982270PMC12455486 | 2025-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.J Am Heart Assoc | PMID 41128134PMC12684792 | 2025-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.Nat Commun | PMID 41188218PMC12586486 | 2025-Nov-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia.Cancer Epidemiol Biomarkers Prev已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40905823PMC12476283 | 2025-Nov-03 | 0.80 | The study is an oncology randomized Phase III trial involving a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. It focuses on cerebrospinal fluid biomarkers of neurotoxicity, not on survival or progression outcomes required for eligibility. | 无 KM 图 |
| Acute Kidney Injury and Neurodevelopmental Outcomes in Extremely Premature Neonates: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure.:CONSORT/入组流程图。 | PMID 41222934PMC12612947 | 2025-Nov-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.Hepatology疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39808820无 PMCID | 2025-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program.Am J Gastroenterol已检查 5 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 multi panel km。 | PMID 39878434PMC12570604 | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.Haematologica | PMID 40207715PMC12580706 | 2025-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study).J Affect DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40378969无 PMCID | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer-Mature Results of the ARTSCAN III Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40543675无 PMCID | 2025-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Obstructive sleep apnea, glycemic control, and cardiovascular risk in young adults with youth-onset type 2 diabetes: results from the TODAY study.J Clin Sleep MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40566988PMC12519451 | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.Retina已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:CONSORT/入组流程图;Fig. 2.:AI 判定为 other;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other;captionless-figure:AI 判定为 other;另有 1 张未列出。 | PMID 40668667PMC12548813 | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.Int J Surg已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:瀑布图;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40693968PMC12626509 | 2025-Nov-01 | 0.45 | The trial is a Phase III randomized controlled trial in oncology with a drug intervention and reports primary results. However, it lacks any explicit time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or associated Kaplan-Meier/HR analysis, which is a required criterion for eligibility. | 无 KM 图 |
| Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.JAMA Intern Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:生活质量量表图。 | PMID 40920404PMC12418220 | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Efficacy of a Preservative-Free Bimatoprost 0.01% Ophthalmic Gel: Results From a Phase III Controlled Trial.J GlaucomaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40952469无 PMCID | 2025-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |